SA
SMMT logo
Summit Therapeutics Inc.(SMMT)
Closing price · checked 8:38 PM ETAbout this dataData status
$9.95▼-0.62 (-5.87%)
Extended:$10.07+0.12 (+1.21%)· 8:38 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Summit Therapeutics Inc. (SMMT)

R&D Expenses

$606.77M

TTM · Period ending: · USD

SMMT logo

SMMT R&D Expenses

Latest reported$606.77M
SMMT R&D Expenses ($46.50K → $606.77M)
High-resolution chart · PNG

What is r&d expenses?

Research and development spending.

SMMT r&d expenses history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it.

Summit Therapeutics Inc. R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)Change
537,674,000+224.32%
165,784,000−71.44%
580,387,000+1,016.15%
51,999,000−39.08%
85,352,000+60.21%
53,274,000+62.50%
32,783,359−33.19%
49,069,000+69.33%
28,979,000+52.91%
18,952,000+12.43%
16,856,000+61.81%
10,417,000+57.57%
6,611,000+39.74%
4,731,000+53.57%
3,080,775+37.44%
2,241,582−39.05%
3,678,000−50.15%
7,378,000−51.89%
15,335,000+164.85%
5,790,000+216.05%
1,832,000+263.06%
504,603+985.17%
46,500—

Frequently asked questions: SMMT r&d expenses

What is Summit Therapeutics Inc. (SMMT)'s current r&d expenses?

Summit Therapeutics Inc. (SMMT)'s latest reported r&d expenses (TTM) is $606.77M as of Sep 30, 2026. Research and development spending.

How much historical r&d expenses data is available for SMMT?

Stock Alarm Pro provides 23 dated annual fiscal periods observations for Summit Therapeutics Inc. (SMMT)'s r&d expenses, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare SMMT's r&d expenses to peers or set an alert?

You can open SMMT's r&d expenses in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on SMMT delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.